Siloton is developing a remote monitoring service to improve care for AMD patients and prevent sight loss. The company is leveraging integrated photonics to address the impact of AMD, which affects 1 in 4 people over the age of 60.

Siloton is developing an at-home monitoring service for the 25% of over 60’s with age-related macular degeneration. This service will reduce the burden of treatment, alleviating pressure on healthcare systems, while helping patients retain their sight for longer. Siloton’s service will combine a next-generation diagnostic imaging device with cloud-based digital health tools that will enable clinicians to deliver an unparalleled quality of care to their patients. Siloton was founded in April 2020 in Bristol, UK and is an alumnus of the Quantum Technologies Enterprise Centre (QTEC) incubator programme. At the core of Siloton’s new generation of diagnostic imaging device is a photonic integrated circuit (PIC) that allows Siloton to realise order of magnitude reductions in size and cost while increasing device robustness.For press enquiries, please contact pressoffice@siloton.com.

COM:SILOTON

Siloton

Analysis Not Available